📇 Rhumatologue · PARIS · (75) · Mixte
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CLINIQUE DU MONT LOUIS
8-10 8 R DE LA FOLIE REGNAULT, 75011 PARIS
GHU APHP SUN SITE TENON
4 R DE LA CHINE, 75970 PARIS CEDEX 20
CABINET DU DR ARMINE IZADIFAR
CENTRE CARDIOLOGIQUE DU NORD 32 RUE DES MOULINS GEMEAUX, 93200 ST DENIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The European respiratory journal · 2020
The European respiratory journal · 2018
The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated. Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg −1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival. In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean± sd age was 61.6±8.9 years, 190 (34.6%) patients had stage II−III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in overall survival between groups (hazard ratio (HR) 1.24, 95% CI 0.92–1.68; p=0.17). There was no difference in the cumulative incidence of recurrence between groups (subdistribution HR 0.94, 95% CI 0.68–1.30; p=0.70). Adjuvant tinzaparin had no detectable impact on overall and recurrence-free survival of patients with completely resected stage I−IIIA NSCLC. These results do not support further clinical evaluation of LMWHs as anti-tumour agents.
The European respiratory journal · 2023
BackgroundLongitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19.MethodsWe collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end of cohort time. All patients had TB and COVID-19; for analysis purposes, deaths were attributed to TB, COVID-19 or both. Survival analysis was performed using Cox proportional risk-regression models, and the log-rank test was used to compare survival and mortality attributed to TB, COVID-19 or both.ResultsOverall, 788 patients with COVID-19 and TB (active or sequelae) were recruited from 31 countries, and 10.8% (n=85) died during the observation period. Survival was significantly lower among patients whose death was attributed to TB and COVID-19versusthose dying because of either TB or COVID-19 alone (p<0.001). Significant adjusted risk factors for TB mortality were higher age (hazard ratio (HR) 1.05, 95% CI 1.03–1.07), HIV infection (HR 2.29, 95% CI 1.02–5.16) and invasive ventilation (HR 4.28, 95% CI 2.34–7.83). For COVID-19 mortality, the adjusted risks were higher age (HR 1.03, 95% CI 1.02–1.04), male sex (HR 2.21, 95% CI 1.24–3.91), oxygen requirement (HR 7.93, 95% CI 3.44–18.26) and invasive ventilation (HR 2.19, 95% CI 1.36–3.53).ConclusionsIn our global cohort, death was the outcome in >10% of patients with TB and COVID-19. A range of demographic and clinical predictors are associated with adverse outcomes.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The European respiratory journal · 2023 · Journal Article
Global Tuberculosis Network and TB/COVID-19 Global Study Group, Casco N, Jorge AL, Palmero DJ, et al.
The European respiratory journal · 2020 · Letter
Tadolini M, Codecasa LR, García-García JM, Blanc FX, et al.
Respiratory medicine and research · 2021 · Journal Article
Raherison-Semjen C, Izadifar A, Russier M, Rolland C, et al.
The European respiratory journal · 2018 · Clinical Trial, Phase III
Meyer G, Besse B, Doubre H, Charles-Nelson A, et al.
Respiratory medicine and research · 2022 · Practice Guideline
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, et al.